OSE Immuno Together

Launch of ose-immuno-ensemble.com to inform all stakeholders of OSE Immunotherapeutics ahead of the September 30, 2025 General Meeting

We are three founding shareholders of OSE Immunotherapeutics (OSE).

We know and love this company. We have led it and made it grow.
We are proud of what OSE has accomplished thanks to its employees and its partners.

We want OSE to express its full potential and full value from its sites in Nantes and Paris.
This is why we want OSE to continue the strategy that, up to now, has made it successful.

Today, we have a disagreement with the Board of Directors regarding the strategy, in particular concerning the clinical development of Lusvertikimab.

The Board’s presentation of the strategy is unclear. What we decode from it would be inconsistent and very risky for OSE’s future and assets.

After several attempts at dialogue, we have resolved to request the dismissal of the current directors at the next General Meeting, scheduled for September 30.

We are not doing this light-heartedly.

We are requesting this dismissal because it is in the interest of:

  • all shareholders,
  • the employees who are caught in the middle of this conflict
  • the industrial, scientific, and institutional partners who trust OSE
  • the patients who are waiting for innovative therapeutic solutions

We are a Trio, but we see that many share our views.

We invite all OSE shareholders and all other OSE stakeholders to join us, so that our company continues along the path of partnerships, success, and medical progress.

 

Together, let’s make OSE and its Nantes R&D center successful.

This will be decided on September 30 with the adoption of our resolutions at the General Meeting.

Dominique Costantini, Emile Loria, and Alexis Peyroles

Close